Funding: CASCADE has been funded through grants BMH4-CT97-2550, QLK2-2000-01431, QLRT-2001-01708, and LSHP-CT-2006-018949 from the European Union. MW and HCB are supported by research grants from sante suisse and the Gottfried and Julia-Bangerter-Rhyner Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: HCB received travel grants, honoraria, and unrestricted research grants from various pharmaceutical companies including, GlaxoSmithKline, Bristol-Myers-Squibb, Gilead, Roche, Abbott, Tibotec, and Boehringer-Ingelheim. The research of MW, JY, and HCB is supported by unrestricted grants from sante suisse and the Gottfried and Julia Bangerter-Rhyner-Foundation. The Medical Research Council, Clinical Trials HIV Group, led by AB, received donated drugs and/or financial support for substudies from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla, Gilead, Tibotec, Roche, GlaxoSmithKline, Indevus, Merck, Novartis, Sanofi Pasteur, and Virco. KP also received honorarium from Tibotec. CS has received funding for research, teaching, and consultancy from several pharmaceutical companies (GlaxoSmithKline, Gilead Sciences, Bristol-Myers Squibb, and Tibotec) over the last few years. CM received travel grants and honoraria from: GlaxoSmithKline, Bristol-Myers-Squibb, Gilead, Roche, Abbott, Tibotec, and Boehringer-Ingelheim. The research of CM is supported by Istituto Superiore di Sanita.
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000239
PRESS-ONLY PREVIEW OF THE ARTICLE: www.plos.org/press/plme-07-02-wolbers.pdf
|Contact: Andrew Hyde|
Public Library of Science